‘Parker’ Tagged Posts

1997 3D VR Flatland at a membership (Pgh) w/Shawn White & Sean Parker

...

 

Supreme Court arguments regarding action that consumers listen to the damage allegedly caused by the generic drugs Sue could tell Parker Waichman LLP

 

19th (PRWEB) March 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of injured victims of defective drugs, is commenting on the latest developments in Bartlett v. Mutual Pharmaceutical Company, U.S. Supreme Court, No. 12-142, An action in which the plaintiff alleged violations of sulindac, a generic version of the steroidal anti-inflammatory drugs (NSAIDs), Clinoril. According to a Reuters report on 18 Was published in March 2013, Mutual Pharmaceutical Co. has asked the High Court, given a $ 21 million judgment plaintiff Karen Bartlett, who caused crash trying sulindac claiming a severe form of Stevens-Johnson syndrome. The Supreme Court was to hear arguments in the case yesterday, Reuters reported.

http://www.reuters.com/article/2013/03/18/us-usa-court-generics-idUSBRE92H09Y20130318

At its difficult for the consumer to sue over alleged violations of generic, Matthew J. McCauley, Senior Litigation Counsel says Parker Waichman LLP. Help decide the outcome of this case future litigation over generic medications. The national injury law firm offers free legal advice to patients allegedly injured defective drugs and medical devices.


According to Reuters

Mutual Pharmaceutical Co. has asked the Supreme Court to overturn the $ 21 million to plaintiffs Karen Bartlett on their generic drugs sulindac. Bartlett claimed sued the company in 2008 that the NSAID medication. Severe form of Stevens-Johnson syndrome, a rare hypersensitivity reaction, which allegedly caused her skin to peel off, causing burn-like lesions over two-thirds of her body Reuters reports that about it for almost two months in a hospital burn unit and has 13 eye surgeries, allegedly because sulindac. Their lawsuit alleges that the reaction left her nearly blind. With scarred lungs and a narrowed esophagus, which makes it hard to swallow The jury awarded them with $ 21 million after two-week trial.

Reuters reports that Mutual tried to overturn the award, arguing that federal law prevents lawsuits like Bartletts, because the manufacturers of generic drugs are required to wear the same design and label as their brand-name counterparts. Bartlett’s claim circumvented this restriction by claiming that sulindac itself was inherently dangerous and defective. Mutual cited the case of PLIVA, Inc. v. MENSING (Nos.09-993, 09-1039 and 09-1501), which means that generic drugmakers could not be held liable for alleged violations are excluded because they are not responsible for what is drugs on the safety label, the company claims that this logic to the design of the product and applies. However, Mai decided unanimously three judges of the first Circuit Court of Appeals in Boston, that the scheme is not to assert claims design defects. Mutual has stopped production and sale of the drug, have the court ruled. Reuters reports that the U.S. Food and Drug Administration (FDA) received reports of adverse skin reactions associated with sulindac.


can be crucial

outcome of the proceedings to determine whether generic makers are liable for alleged violations by their drugs, according to Reuters. About 80 percent of prescriptions are filled in the U.S. generic. Even if a doctor prescribed a brand name drug, state laws allow pharmacists automatically replace it with a generic. It is much harder for consumers to sue for generics makers if the court finds that state requirements are superseded by federal law.

Parker Waichman LLP is a leading mass tort, environmental damage and personal injury law firm that represents plaintiffs in personal injury lawsuits nationwide. The company has offices in New York, Long Iceland, New Jersey, Washington, DC and Florida. For more than two decades, Parker Waichman LLP has assisted thousands of clients in a fair compensation from the negligence of others. For more information on Parker Waichman LLP, please visit:. Http :/ / www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636)

contact:
Parker Waichman LLP

Gary Falkowitz, Managing Attorney??

(800) LAW-INFO

(800) 529-4636

http://www.yourlawyer.com


Parker & Waichman, LLP Contacted by Viagra, Cialis & Levitra Users Claiming Vision Problems, Blindness & Other Side Effects; Firm to File Lawsuits in Coming Weeks

 

Parker & Waichman, LLP Contacted by Viagra, Cialis & Levitra Users Claiming Vision Problems, Blindness & Other Side Effects; Firm to File Lawsuits in Coming Weeks











New York, NY (PRWEB) June 3, 2005

For the past 6 months, Parker & Waichman, LLP (www.yourlawyer.com) has been contacted by prospective clients who claim to have suffered loss of vision as a result of using the erectile dysfunction drug Viagra (sildenafil citrate). Last week, the FDA announced that it is investigating a link between erectile dysfunction drugs and NAION – nonarteritic anterior ischemic optic neuropathy – which can cause blindness. Parker & Waichman, LLP has also received a significant number of inquiries from Cialis and Levitra users who claim to have suffered vision loss after using those drugs. Viagra, Cialis and Levitra patients can learn more by visiting http://www.yourlawyer.com/practice/overview.htm?topic=Viagra.

In its announcement last week, The Food and Drug Administration said it had received 43 reports of varying degrees of vision loss, including blindness, among users of erectile dysfunction drugs. There were 38 reports of blindness among Viagra users (Six patients had vision loss within 24 hours after use of Viagra), four among Cialis users and one among Levitra users. Eli Lilly & Co. (NYSE: LLY) and ICOS Corp. (NASDAQ: ICOS), the makers of Cialis, have already added a warning about possible vision loss to the drug’s label. The FDA has said it is in discussions with Pfizer Inc. (NYSE: PFE) the maker of Viagra, and the makers of Levitra, Bayer AG (NYSE: BAY), GlaxoSmithKline PLC (NYSE: GSK) and Schering Plough CP (NYSE: SGP) about warnings on those drugs’ labels. Over 30 million men worldwide have used an erectile dysfunction drug since Viagra came onto the market in 1998.

NAION occurs when blood flow to the optic nerve is blocked. NAION can be temporary, but it is usually permanent and often leads to legal blindness. Parker & Waichman, LLP continues to offer free case consultations to Viagra, Levitra and Cialis users and their families. Patients can click the appropriate link below for a free consultation: Viagra Patient Case Consultation: http://www.yourlawyer.com/practice/overview.htm?topic=Viagra

Cialis Patient Case Consultation:

http://www.yourlawyer.com/practice/overview.htm?topic=Cialis

Levitra Patient Case Consultation: http://www.yourlawyer.com/practice/overview.htm?topic=Levitra

For more information on Parker & Waichman, LLP please visit: (http://www.yourlawyer.com) or call 1-800-LAW-INFO (1-800-529-4636).

Contact:

Parker & Waichman, LLP

David Krangle, Esq.

(800) LAW-INFO (800-529-4636) (toll free)

dkrangle@yourlawyer.com

http://www.yourlawyer.com

# # #






















VocusВ©Copyright 1997-2010, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.







Parker & Waichman, LLP Files Suit Against Ortho-McNeil Pharmaceutical, Inc. on Behalf of Victim of Ortho Evra Birth Control Patch

 

Parker & Waichman, LLP Files Suit Against Ortho-McNeil Pharmaceutical, Inc. on Behalf of Victim of Ortho Evra Birth Control Patch











New York, NY (PRWEB) February 24, 2006

Parker & Waichman, LLP (http://www.yourlawyer.com) announced that it has filed suit against Ortho-McNeil Pharmaceutical, Inc., a division of Johnson and Johnson Inc., on behalf of a 33-year-old woman who suffered a venous thrombosis (blood clot) and stroke after using the Ortho Evra contraceptive patch for 6 months. In February 2004, the plaintiff began suffering from headaches, nausea and vomiting. Shortly thereafter, the plaintiff’s conditions worsened, and she was taken to the emergency room at the Henry Medical Center in Stockbridge, Georgia. Diagnostic tests revealed venous thrombosis and stroke. The plaintiff was subsequently airlifted to Emory University Hospital and was admitted to the Neuro Intensive Care Unit where she underwent Heparin and Coumadin (anticoagulant) therapy. The plaintiff will likely undergo prolonged treatment with these medications, which may be necessary for the remainder of her life. The suit was filed in the United States District Court for the District of New Jersey in Newark, New Jersey (Docket #06-cv-713). For more information on Ortho Evra please visit http://www.orthopatchlawsuit.com or http://www.yourlawyer.com/topics/overview/Ortho_Evra_Patch.

On November 10, 2005, Ortho McNeil, in conjunction with the FDA, issued a warning about the increased risks of blood clots associated with Ortho Evra. In the new warning, Ortho-McNeil admitted for the first time that women who use the patch will be exposed to up to 60% more estrogen than they would be exposed to if they were taking a birth control pill with 35 micrograms of estrogen. The patch is only intended to deliver 20 micrograms of estrogen. The FDA’s announcement on this warning can be found at http://www.fda.gov/bbs/topics/news/2005/NEW01262.html. It is widely understood that increased exposure to estrogen greatly increases the risk of blood clots, which can cause serious injury or death.

Venous thrombosis is a blood clot formation in the veins that most commonly forms in the veins of the legs. The thrombus can interfere with circulation; it may break off and travel through the blood stream, which can cause pulmonary embolism or stroke. Treatment may include long term use of anticoagulant medications and/or surgery. The new warnings from the FDA and Ortho-McNeil indicate that the risk of developing blood clots may be significantly higher with the Ortho Evra patch than with oral contraceptives.

Stroke occurs when the blood supply to a part of the brain is suddenly interrupted. In brain tissue, a reduction of blood flow can damage or kill brain cells. Death of brain tissue can lead to loss of the function controlled by that tissue. Stroke is an extremely serious medical condition that often leads to adult disability and death. It is important to identify a stroke as early as possible because patients who are treated earlier are more likely to survive and have better recoveries. The new warnings from the FDA and Ortho-McNeil indicate that the risk of stroke may be significantly higher with the Ortho Evra patch than with oral contraceptives.

It is alleged that Ortho-McNeil was aware of the increased medical risks associated with Ortho Evra before the drug was approved and that, once approved, the company failed to adequately warn patients about these risks. Evidence shows that the risk of blood clots, heart attack and stroke associated with Ortho Evra is significantly higher than with oral contraceptive pills. The incidence of embolisms and thrombotic injuries in Phase III trials of Ortho Evra was reportedly six times greater than the incidence of such events in oral contraceptives using the hormone levonorgestral. The FDA has logged 9,116 reports of adverse reactions to the patch in a 17 month period, whereas Ortho Tri-Cyclen, a birth control pill, only generated 1,237 adverse reports in a six year period. During a 12 month period, 44 serious injuries or deaths have been associated with Ortho Evra, whereas only 17 such reports were linked to the birth control pill during a similar time period. The pattern is further magnified when usage rates are considered: Ortho Tri-Cyclen has six times the number of users as Ortho Evra.

Ortho Evra is an adhesive, transdermal birth control patch that is worn on the torso. The patch is intended to release 150 mcg of norelgestromin and 20 mcg of ethinyl estradiol into the bloodstream per 24 hours. It is replaced once a week for three weeks, and no patch is worn during the fourth week during menstruation. The regimen is then repeated. Ortho Evra was approved by the FDA in November 2001, and over 4 million women have used Ortho Evra since its approval. Ortho Evra continues to be marketed aggressively to both consumers and physicians.

About Parker & Waichman, LLP

Parker & Waichman, LLP is a leading products liability and personal injury law firm that represents plaintiffs nationwide. The firm has offices in New York and New Jersey. Parker & Waichman, LLP has assisted thousands of clients in receiving fair compensation for injuries resulting from defective medications and medical devices. For more information on Parker & Waichman, LLP please visit: (http://www.yourlawyer.com) or call 1-800-LAW-INFO (1-800-529-4636).

CONTACT: Parker & Waichman, LLP

В В В В В В В В  Jason Mark, Esq.

В В В В В В В В  Melanie H. Muhlstock, Esq.

В В В В В В В В  1-800-LAW-INFO

В В В В В В В В  1-800-529-4636 — toll-free

В В В В В В В В  http://www.yourlawyer.com

# # #




















VocusВ©Copyright 1997-2010, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.







More Ortho Tri-Cyclen Press Releases

Parker & Waichman, LLP Urges Current and Former Bextra and Celebrex Users to Explore Legal Options

 

Parker & Waichman, LLP Urges Current and Former Bextra and Celebrex Users to Explore Legal Options











NEW YORK (PRWEB) April 14, 2005

Parker & Waichman, LLP (www.yourlawyer.com) has been contacted by numerous current and former Bextra users who believe they were injured as a result of using the drug. Parker & Waichman, LLP continues to evaluate cases and consult with prospective clients who have experienced heart attacks and strokes as well as those who have been diagnosed with Stevens Johnson Syndrome and Toxic Epidermal Necrolysis during the use of Bextra.

Parker & Waichman, LLP and Seeger Weiss LLP filed the first lawsuit in the United States in 2004 against Pfizer claiming their clients sustained injuries and resulting death as a result of ingestion of the drug Bextra.

Parker & Waichman, LLP has also received a significant amount of inquiries from patients who suffered heart attacks and strokes while using Celebrex. Both Bextra and Celebrex patients can receive a free case evaluation by visiting www.bextralegalhelp.com and www.celebrexlawyernetwork.com.

Based on the number of Celebrex inquiries and the research data available, Parker & Waichman, LLP supports Public Citizen’s view that Celebrex should also be removed from the market. Parker & Waichman, LLP believes that the failure to remove Celebrex from the market puts millions of people at an unnecessary risk.

An unpublished study finished in 2000 indicated increased cardiac risks associated with Celebrex. A more recent study sponsored by the National Cancer Institute discovered that Celebrex’s risk of causing a major cardiovascular event was two-and-a-half times greater than that for people taking a placebo. In 2004, almost twice as many prescriptions were written for Celebrex as for Bextra – 23.9 million prescriptions compared to 12.9 million.

“The removal of Bextra is a step in the right direction but we cannot ignore the high rate of serious side effects associated with Celebrex,” commented Jerrold S. Parker, one of the founding partners of Parker & Waichman, LLP. “We continue to believe that Celebrex is a dangerous drug that is no more effective in treating pain and no better tolerated than traditional NSAIDS. We will continue to represent victims of all COX-2 drugs whose lives have been impaired or lost.” For more information on Celebrex, please visit www.yourlawyer.com/practice/overview.htm?topic=Celebrex. For more information on Bextra please www.yourlawyer.com/practice/overview.htm?topic=Bextra

For more information on Parker & Waichman, LLP please visit: (http://www.yourlawyer.com) or call 1-800-LAW-INFO (1-800-529-4636). For more information on Public Citizen please visit www.worstpills.org.

Contact:

Parker & Waichman, LLP

David Krangle, Esq.

(800) LAW-INFO (800-529-4636) (toll free)

dkrangle@yourlawyer.com

http://www.yourlawyer.com

###




















VocusВ©Copyright 1997-2010, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.







Related Celebrex Press Releases